Will Tonix Pharmaceuticals stock go up?

According to Danelfin AI, Tonix Pharmaceuticals has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (52.00%) is +1.18% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Tonix Pharmaceuticals stock?

The Tonix Pharmaceuticals target price is $12.36 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Tonix Pharmaceuticals stock right now?

Tonix Pharmaceuticals has today a Hold rating (AI Score 5/10), according to Danelfin AI. Its probability of beating the market in 3 months (52.00%) is +1.18% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Tonix Pharmaceuticals stock is a good buy .

Is Tonix Pharmaceuticals undervalued right now?

Based on analysts, the average price target downside for Tonix Pharmaceuticals is 0.00% (1Y). According to Danelfin AI, Tonix Pharmaceuticals has today an AI Score of 5/10 (Hold Rating).

What was the price range of Tonix Pharmaceuticals stock over the past 12 months?

The Tonix Pharmaceuticals stock price range over the past 12 months has been $10.65 - $61.57.

What is going on with Tonix Pharmaceuticals stock in the last 3 months?

The Tonix Pharmaceuticals stock performance in the last quarter has been -9.64%.

Does Tonix Pharmaceuticals offer dividend payments?

No, Tonix Pharmaceuticals does not currently pay dividends.

What is the current market capitalization of Tonix Pharmaceuticals?

Tonix Pharmaceuticals's market cap is $196.71M, as of 2026-07-03 08:00.

Tonix Pharmaceuticals Holding Corp (TNXP) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

TNXP AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Tonix Pharmaceuticals Holding Corp today receives an AI Score of 5/10, which translates to a Hold rating. The stock has a 52% probability of outperforming the market in the next 3 months, which is 1% higher than the average probability of any stock (51%). Among the top positive contributors, the Fundamentals Impact (Long Tail) adds +1.81% to the probability, while the Industry (Biotechnology) contributes +0.51% and Cash per Share (MRQ) in the top 10% adds +0.46%. On the negative side, the Chart Pattern (504d) detracts -0.77%, Basic EPS Consolidated in the bottom 10% reduces probability by -0.72%, and Beta in the top 20% detracts -0.65%. Notable data points include a Cash per Share (MRQ) of $11.64 in the top 10%, indicating strong liquidity, and Tangible Shareholders' Equity of $227.02M in the top 50%, reflecting solid net worth. However, Operating Cash Flow (Qtr Discrete) is in the bottom 10% at -$42.32M, and Basic EPS is also in the bottom 10% at -$2.93, highlighting weak operational performance and profitability. The Fear & Greed Index at 31 suggests extreme fear, which can weigh on sentiment. Overall, the mixed signals—positive liquidity and industry tailwinds versus poor fundamentals and high volatility—balance out, resulting in a HOLD rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Valuation+2.51%
How the stock is priced relative to its fundamentals
Earnings Quality+1.01%
Stability and reliability of reported earnings
Sentiment+0.46%
How analysts and the market view the stock
Size & Liquidity+0.29%
Company size and trading liquidity

Volatility-1.99%
How much the stock price tends to fluctuate
Growth-0.72%
Expected pace of revenue and earnings expansion
Profitability-0.20%
Profitability and operating efficiency metrics
Momentum-0.18%
Direction and strength of recent price movements

TNXP probability advantage of beating the market (3M):

+1.18%

AI Score

Hold

Tonix Pharmaceuticals (TNXP) has an AI Score of 5/10 (Hold) because, according to an overall analysis, it has a probability advantage of +1.18% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of TNXP (52.00%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
TNXP probability advantage of beating the market (3M)+1.18%
TNXP probability of beating the market (3M)52.00%

TNXP probability advantage of beating the market (3M): +1.18%

The AI-powered overall analysis of Tonix Pharmaceuticals (TNXP) is based on the 26 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of TNXP:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+1.81%
Fundamental	Operating Cash Flow (Qtr Discrete)	-42.32	N/A	+1.01%
Technical	Chart Pattern (504d)	figure_45	N/A	-0.77%
Fundamental	Basic EPS Consolidated	-2.93	N/A	-0.72%
Technical	Beta	1.64		-0.65%
Technical	ATR (180d Volatility)	289.52K		-0.60%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.58%
Technical	Maximum Volatility	8.87%		-0.52%
Sentiment	Industry (GICS)	Biotechnology	N/A	+0.51%
Fundamental	Cash per Share (MRQ)	11.64		+0.46%
Fundamental	Upgrade to unlock			+0.42%
Technical	Upgrade to unlock			+0.35%
Fundamental	Upgrade to unlock			+0.29%
Sentiment	Upgrade to unlock			+0.28%
Sentiment	Upgrade to unlock			+0.28%

Rest of Alpha Signals: -0.39%

TNXP probability advantage of beating the market (3M)Total:+1.18%
TNXP AI Score

Significant changes Vs previous day

TNXP Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$12.36
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

TNXP Proven Hold Signal & Price Forecast

This is the price chart for TNXP from January 2, 2026 until today. The chart indicates, in yellow, the 50 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

TNXP Average Past Performance & Win Rate

Three months after its 674 Hold signals since July 2026, TNXP had an average performance of xxxxxxx and a xxxxxx Win rate (positive performance).

674 Past TNXP Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-67.23%
Average Alpha				-78.51%
Win Rate (% Positive Perf.)				5.77%
% Positive Alpha				5.41%

TNXP Frequently Asked Questions

Will Tonix Pharmaceuticals stock go up?
According to Danelfin AI, Tonix Pharmaceuticals has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (52.00%) is +1.18% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Tonix Pharmaceuticals stock?
Is it a good time to buy, sell, or hold Tonix Pharmaceuticals stock right now?
Is Tonix Pharmaceuticals undervalued right now?
What was the price range of Tonix Pharmaceuticals stock over the past 12 months?
What is going on with Tonix Pharmaceuticals stock in the last 3 months?
Does Tonix Pharmaceuticals offer dividend payments?
What is the current market capitalization of Tonix Pharmaceuticals?

Tonix Pharmaceuticals Holding Corp Company Profile

Tonix Pharmaceuticals Holding Corp., grounded in the biopharmaceutical sector, directs its operations towards the research, development and commercialization of innovative therapeutics primed for disease prevention and treatments to mitigate human suffering. Currently, it supplies the market with Zembrace SymTouch and Tosymra, specialized medicines geared for handling acute migraines in adults, aura presence notwithstanding.

Proceeding further into therapeutic innovation, Tonix's developmental lineup puts a spotlight on addressing disorders related to the central nervous system. On top of its agenda is filing a New Drug Application (NDA) with the FDA for TNX-102 SL - a unique sublingual cyclobenzaprine HCl tablet whose potency against fibromyalgia management has been endorsed by successful completion of two Phase 3 studies.

Venturing into post-COVID-19 healthcare, TNX-102 SL is concurrently being engineered to manage long COVID symptoms that replicate fibromyalgia. Transitioning to treating substance misuse issues, Tonix showcases TNX-1300 (cocaine esterase), an innovative biologic that actively counteracts cocaine intoxication effects and has earned fast track status via FDA’s breakthrough therapy designation.

Undertaking rare diseases such as Prader-Willi syndrome (PWS), Tonix explores potential therapeutic pathways using TNX-2900, which introduces potentiated oxytocin through an intranasal course. Not ignoring immunology sphere needs, it bolsters organ transplantation success rates while combating autoimmunity and cancer with therapies like TNX-1500 - a humanized monoclonal antibody targeting CD40-Ligand.

In addition to these fights against various medical challenges, Tonix confronts infectious diseases with pipelines integrating innovations like TNX-801 - a smallpox protective vaccine that extends its function towards multiplayer pox prevention. It also acts as a live virus vaccine platform for other conditions including COVID-19 protection via TNX-1800.

Broadening its infectious disease portfolio, Tonix anticipates the inclusion of TNX-3900 and TNX-4000 - an upcoming range of broad-spectrum oral antivirals. Founded in 2007, Tonix Pharmaceuticals plants its corporate roots in Chatham, New Jersey, serving as its operational hub and headquarters.

Sector:Health Care
Country:United States
Industry:
Address:26 Main Street, Suite 101, Chatham
Employees:142
Website:tonixpharma.com

Pros

Diversified therapeutic pipeline across multiple disease areas

Proprietary drug formulations offering patent protection

Focus on indications with unmet medical needs

Potential for orphan drug market exclusivity

Accumulation of intellectual property through patents and licenses

Cons

Substantial capital requirements for drug development

Inherent risk of clinical trial failures

Lengthy and complex regulatory approval processes

Reliance on third-party contract manufacturing organizations

Competition from established pharmaceutical companies

Company	AI Score	Compare
TENXTenax Therapeutics Inc
BTAIBioXcel Therapeutics Inc
NRXPNRX Pharmaceuticals Inc
NRIXNurix Therapeutics Inc

Company	AI Score	Compare
TENXTenax Therapeutics Inc
BTAIBioXcel Therapeutics Inc
NRXPNRX Pharmaceuticals Inc
NRIXNurix Therapeutics Inc

TNXP Stock AI Analysis High Risk